Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891363149> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W2891363149 abstract "e14545 Background: Tumor specific TILs can be in vitro expanded and have the ability to induce complete and durable tumor regression in some patients following ACT. In this preclinical study we investigated the feasibility of expanding TILs from sarcomas, as well as performing functional in vitro analyses on these. Methods: Fresh tumor samples from sarcoma patients were obtained, and TILs were isolated and expanded in growth medium containing IL-2. In a sub study, we investigated the effect of adding an agonistic CD137 antibody (Urelumab, BMS) and/or an anti-CD3 antibody (OKT3) to the medium. Phenotype and functional analyses was performed using flow cytometry and IFNγ-Elispot. Results: Tumor samples from 30 patients with various types of sarcomas were obtained, and we were able to expand a minimum of 40 million TILs from 27 of these. Mean expansion times were 32 days (14 - 61). 87,7 % (36,4 – 99,1) of these cells were CD3+, and of these, 66,7 % (16,3 – 99,1) were CD4+, and 21,8 % (0,1 – 50,6) were CD8+. A sub study revealed that adding anti-CD137 and/or OKT3 increased total yield of TILs; anti-CD137 skewed the phenotype significantly towards more CD8+ TILs and in some cases NK cells and γδ T cells. TILs from 8 of 17 tested tumor samples from four different sarcoma subtypes (undifferentiated pleomorphic sarcoma, myxofibrosarcoma, myxoid liposarcoma and osteosarcoma) demonstrated reactivity against autologous tumor cells using IFNγ-Elispot (40 – 500 spots per 100.000 TILs). In TILs stimulated with anti-CD137 the reactivity increased. Conclusions: We were able to expand TILs from 90 % of the acquired tumor samples to numbers needed for possible future clinical ACT implementation. Expanded TILs were a mix of CD4+ and CD8+ with CD4+ being predominant. Approximately half of the TIL cultures showed some degree of in vitro tumor reactivity as determined by Elispot. Early analyses suggest that addition of anti-CD137 could influence expansion time, phenotype, and functional capacity of the expanded TILs. Based on these results, we conclude that it is feasible to translate TIL based ACT into clinical testing in sarcoma patients." @default.
- W2891363149 created "2018-09-27" @default.
- W2891363149 creator A5002728271 @default.
- W2891363149 creator A5005631682 @default.
- W2891363149 creator A5033765791 @default.
- W2891363149 creator A5067300021 @default.
- W2891363149 creator A5073488854 @default.
- W2891363149 creator A5079452497 @default.
- W2891363149 creator A5084945641 @default.
- W2891363149 creator A5090097395 @default.
- W2891363149 date "2017-05-20" @default.
- W2891363149 modified "2023-09-22" @default.
- W2891363149 title "Preclinical development of tumor-infiltrating lymphocyte (TIL) based adoptive cell transfer (ACT) immunotherapy for patients with sarcoma and the potential benefit of anti-CD137 stimulation." @default.
- W2891363149 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e14545" @default.
- W2891363149 hasPublicationYear "2017" @default.
- W2891363149 type Work @default.
- W2891363149 sameAs 2891363149 @default.
- W2891363149 citedByCount "0" @default.
- W2891363149 crossrefType "journal-article" @default.
- W2891363149 hasAuthorship W2891363149A5002728271 @default.
- W2891363149 hasAuthorship W2891363149A5005631682 @default.
- W2891363149 hasAuthorship W2891363149A5033765791 @default.
- W2891363149 hasAuthorship W2891363149A5067300021 @default.
- W2891363149 hasAuthorship W2891363149A5073488854 @default.
- W2891363149 hasAuthorship W2891363149A5079452497 @default.
- W2891363149 hasAuthorship W2891363149A5084945641 @default.
- W2891363149 hasAuthorship W2891363149A5090097395 @default.
- W2891363149 hasConcept C114684123 @default.
- W2891363149 hasConcept C142724271 @default.
- W2891363149 hasConcept C167672396 @default.
- W2891363149 hasConcept C202751555 @default.
- W2891363149 hasConcept C203014093 @default.
- W2891363149 hasConcept C2776090121 @default.
- W2891363149 hasConcept C2777701055 @default.
- W2891363149 hasConcept C2778256501 @default.
- W2891363149 hasConcept C2778326572 @default.
- W2891363149 hasConcept C2779053233 @default.
- W2891363149 hasConcept C2780249625 @default.
- W2891363149 hasConcept C502942594 @default.
- W2891363149 hasConcept C553184892 @default.
- W2891363149 hasConcept C55493867 @default.
- W2891363149 hasConcept C71924100 @default.
- W2891363149 hasConcept C86803240 @default.
- W2891363149 hasConcept C8891405 @default.
- W2891363149 hasConcept C90375314 @default.
- W2891363149 hasConceptScore W2891363149C114684123 @default.
- W2891363149 hasConceptScore W2891363149C142724271 @default.
- W2891363149 hasConceptScore W2891363149C167672396 @default.
- W2891363149 hasConceptScore W2891363149C202751555 @default.
- W2891363149 hasConceptScore W2891363149C203014093 @default.
- W2891363149 hasConceptScore W2891363149C2776090121 @default.
- W2891363149 hasConceptScore W2891363149C2777701055 @default.
- W2891363149 hasConceptScore W2891363149C2778256501 @default.
- W2891363149 hasConceptScore W2891363149C2778326572 @default.
- W2891363149 hasConceptScore W2891363149C2779053233 @default.
- W2891363149 hasConceptScore W2891363149C2780249625 @default.
- W2891363149 hasConceptScore W2891363149C502942594 @default.
- W2891363149 hasConceptScore W2891363149C553184892 @default.
- W2891363149 hasConceptScore W2891363149C55493867 @default.
- W2891363149 hasConceptScore W2891363149C71924100 @default.
- W2891363149 hasConceptScore W2891363149C86803240 @default.
- W2891363149 hasConceptScore W2891363149C8891405 @default.
- W2891363149 hasConceptScore W2891363149C90375314 @default.
- W2891363149 hasLocation W28913631491 @default.
- W2891363149 hasOpenAccess W2891363149 @default.
- W2891363149 hasPrimaryLocation W28913631491 @default.
- W2891363149 hasRelatedWork W1006088287 @default.
- W2891363149 hasRelatedWork W1981831828 @default.
- W2891363149 hasRelatedWork W2036481615 @default.
- W2891363149 hasRelatedWork W2058899594 @default.
- W2891363149 hasRelatedWork W2155959680 @default.
- W2891363149 hasRelatedWork W2328665324 @default.
- W2891363149 hasRelatedWork W2330935911 @default.
- W2891363149 hasRelatedWork W2417813450 @default.
- W2891363149 hasRelatedWork W2531637633 @default.
- W2891363149 hasRelatedWork W2558713142 @default.
- W2891363149 hasRelatedWork W2627004733 @default.
- W2891363149 hasRelatedWork W2911757002 @default.
- W2891363149 hasRelatedWork W2954857168 @default.
- W2891363149 hasRelatedWork W2991746129 @default.
- W2891363149 hasRelatedWork W3029035275 @default.
- W2891363149 hasRelatedWork W3083602356 @default.
- W2891363149 hasRelatedWork W3092580968 @default.
- W2891363149 hasRelatedWork W3136105674 @default.
- W2891363149 hasRelatedWork W3162658861 @default.
- W2891363149 hasRelatedWork W3211806216 @default.
- W2891363149 isParatext "false" @default.
- W2891363149 isRetracted "false" @default.
- W2891363149 magId "2891363149" @default.
- W2891363149 workType "article" @default.